Fulvestrant (Faslodex)

01/01/2019 - "The selective ER degrader (SERD), fulvestrant, is effective in patients with metastatic breast cancer, but its intramuscular route of administration and low bioavailability are major clinical limitations. "
01/01/2023 - "Food and Drug Administration for human breast cancer treatment, along with fulvestrant, is effective for CMT treatment. "
05/01/2008 - "We conclude that, because of its therapeutic efficacy and its seemingly minimal effect on bone integrity, fulvestrant represents a new option for the hormonal treatment of breast cancer that deserves further clinical evaluation."
01/01/2019 - "Fulvestrant 500 mg is an effective and safe treatment for patients with advanced or recurrent breast cancer after prior endocrine treatment."
02/01/2006 - "Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents."

01/23/2018 - "Importantly, such enhanced efficacy of ZB716 was shown to be attributable to its markedly higher bioavailability, as evidenced in the final plasma and tumor tissue concentrations of ZB716 in mice where drug concentrations were found significantly higher than in the fulvestrant treatment group."
01/15/1994 - "Treatment with ICI 182780 also resulted in a significant reduction in pS2 expression (P < 0.05) but this appeared unrelated to tumor ER status. "
01/23/2018 - "Moreover, in both the MCF-7 xenograft and a patient derived xenograft model, orally administered ZB716 showed superior efficacy in blocking tumor growth when compared to fulvestrant. "
09/11/2014 - "A single-agent AKT inhibitor combined with fulvestrant conferred superior efficacy in overcoming resistance, inducing apoptosis and tumor regression. "
05/01/2014 - "These results showed that combination of fulvestrant and chemotherapeutic agents might provide an effective treatment for ER- MDR breast cancers. "

10/01/2019 - "Fulvestrant treatment benefited patients with lungw/o liver or nonvisceral metastases. "
05/01/2022 - "In June 2019, new multiple lung metastases appeared, and the patient was switched from ANA to fulvestrant, after which complete response was achieved in 6 months. "
10/01/2019 - "Fulvestrant induced a longer PFS in patients with non-visceral metastasis, and also in those with lung metastasis without liver or other organ involvement."
01/01/2018 - "Nineteen patients received fulvestrant, 10 of whom had visceral metastasis. "
09/15/2017 - "Among endocrine sensitive women, longer PFS was associated with fulvestrant in first-line, single metastasis and no visceral involvement (p=0.01, 0.003 and 0.01). "

06/01/2023 - "Subsequent positron-emission tomography/computed tomography imaging showed disease progression, and she was started on fulvestrant. "
01/01/2022 - "Fulvestrant was discontinued predominantly due to disease progression, with 3% discontinued solely due to adverse events. "
04/01/2018 - "Six had experienced disease progression on fulvestrant. "
11/01/2014 - "Fulvestrant was administered but disease progression was observed after 3 months. "
09/01/2012 - "twice daily on day 1 and day 4 weekly) after disease progression, continuing fulvestrant at the same dose. "

01/01/2018 - "Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer."
04/01/2015 - "However, fulvestrant, an anti-estrogen-based endocrine therapeutic treatment, shows limited effects for non-small cell lung cancer (NSCLC) in phase II clinical trials. "
04/01/2014 - "Fulvestrant increases gefitinib sensitivity in non-small cell lung cancer cells by upregulating let-7c expression."
05/01/2012 - "Inhibition of non-small-cell lung cancer growth by combined fulvestrant and vandetanib."
04/01/2009 - "Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer."